Dexcom Recalls Stolen Sensors

On May 26, 2026, Dexcom, Inc. initiated an urgent medical device correction involving select Dexcom G7® continuous glucose monitoring (CGM) sensors after identifying that two lots originally designated as scrap and intended for destruction were stolen during the destruction process and then sold by third parties. The issue primarily affects the United States, and Dexcom traced the distribution of the stolen product to Pharmsource, LLC, which is not an authorized Dexcom distributor. The affected product was scrapped because it did not meet Dexcom quality standards. Specifically, one lot was associated with insufficient sterilization, and the other had an elevated internal testing failure rate. Dexcom stated that unknown storage and handling conditions during unauthorized distribution may create additional risk. Additional recall information and serial number verification are available at Dexcom’s theft-check site www.dexcom.com/theft-check. Dexcom also provides a list of authorized suppliers at www.dexcom.com/dexcom-suppliers. Dexcom G7 is FDA cleared for the management of diabetes mellitus in persons aged 2 years or older, indicated for CGM to replace fingerstick blood glucose testing for diabetes treatment decisions and to provide alerts for hypoglycemia and hyperglycemia. To read more details about the recall, see here.